Abstract

Glioblastoma (GB) remains a lethal disease despite current standard treatment with maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that hinders drug development and study of GB therapeutic response is the lack of an appropriate in vitro model that represents the complexity of patients' tumours. To address these limitations, we have established patient-derived GB organoids (GBOs) that reflect the complexity, heterogeneity and resistance to clinical therapies of the original tumour tissue.  We have shown GBOs recapitulate GB therapy resistance and are as such highly efficient platform to assess the specific responses of GB patients to radiotherapy to further explore therapy resistance. 

Department of Genetic Toxicology and Cancer Biology, Ljubljana, Slovenia

EU Horizon Europe Research and Innovation Program CutCancer